drugset / Trial / NCT01455649

Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults

NCT01455649

Phase 4 Unknown 30 enrolled Deise de Boni Monteiro de Carvalho
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the efficacy and safety in the use of everolimus, with its onset after 3 months of treatment with calcineurin inhibitor.

Timeline

Start
2011-11
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide
Subject Everolimus Small molecule 1 mg
Comparator Tacrolimus Small molecule

Indications

No indication recorded.